I do not accept that, because the randomised badger culling trial, cited by many hon. Members today, showed that culling contributed to a significant reduction in disease in the areas where it ran. It also showed that, even in those areas that had a slow start, where less than 40% of the badgers were culled in year one, there was still a significant reduction in the incidence of the disease provided the cull was sustained in subsequent years.
The Government have developed an ambitious and comprehensive plan for containing the spread of the disease through our 25-year strategy. It has several components, but at its heart is a recognition of a simple and unavoidable fact: there is no magic solution and no one measure will eradicate the disease on its own. TB is an incredibly difficult disease to fight and we need a range of different measure to tackle it.
Some, such as the hon. Member for Brighton, Pavilion (Caroline Lucas), have suggested that vaccination is an easy answer. I wish it were that simple, but it is not. Members will remember that last year, there were concerns about the Schmallenberg virus, a disease that affects sheep. It was relatively straightforward to develop a vaccine that was virtually 100% effective, and the disease is now fully under control. TB is not a simple virus. It is a complex bacterial disease. The bacteria reside inside the cell walls of the host, which makes it incredibly difficult to develop an effective vaccine. As a result, the current BCG vaccine provides only limited protection in about 60% of cases, and even then, the level of protection given is variable. Notwithstanding those difficulties and limitations, we are nevertheless investing large amounts of money in developing methods of deploying vaccine to both badgers and cattle, because,
although vaccination is not a solution on its own, it could have a role in creating buffer zones or containing the spread of the disease.
Since 1994, more than £43 million has been spent on developing the cattle vaccine and the oral badger vaccine. We have committed to investing a further £15.5 million in vaccine deployment over the spending review period.